Hikal Q2 FY27 Earnings Call — Analysis (NSE: HIKAL)
Hikal reported Q2FY27 revenue of ₹434 Cr with an EBITDA margin of 10.3% and a net loss of ₹6 Cr, weighed down by high raw material inflation and ₹20 Cr annualized US FDA remediation costs, while reiterating FY27 guidance for mid-teens revenue growth on expected H2 recovery.
Result quality: watch — Loss narrowed. Management sentiment: optimistic.
The take
Q2FY27 Revenue from Operations ₹434 Cr . New guidance — 12 months post FDA clearance pharma revenue impact from us f… ~₹150 Cr revenue, ~45-46% contribution . New story: US FDA remediation and regulatory recovery .
Results
Revenue stood at ₹434 Cr with EBITDA of ₹45 Cr (10.3% margin) and PAT of -₹6 Cr for Q2FY27.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹434 Cr | none · Q2FY27 · reported quarter | |
| EBITDA | ₹45 Cr | none · Q2FY27 · reported quarter | |
| EBITDA Margin | 10.3% | none · Q2FY27 · reported quarter | |
| PAT | -₹6 Cr | none · Q2FY27 · reported quarter | |
| H1 Revenue from Operations | ₹837 Cr | none · H1FY27 · first half | |
| H1 EBITDA | ₹82 Cr | none · H1FY27 · first half | |
| H1 EBITDA Margin | 9.8% | none · H1FY27 · first half | |
| H1 PAT | -₹14 Cr | none · H1FY27 · first half | |
| Pharmaceuticals Revenue | ₹278 Cr | none · Q2FY27 · segment revenue | |
| Pharmaceuticals EBIT | ₹13 Cr | none · Q2FY27 · segment EBIT | |
| Pharmaceuticals EBIT Margin | 4.6% | none · Q2FY27 · segment EBIT margin | |
| Crop Protection Revenue | ₹156 Cr | none · Q2FY27 · segment revenue | |
| Crop Protection EBIT | -₹2 Cr | none · Q2FY27 · segment EBIT | |
| Crop Protection EBIT Margin | -1.5% | none · Q2FY27 · segment EBIT margin | |
| H1 Capex | ₹81 Cr | none · H1FY27 · H1FY27 additions | |
| Debt to Equity | 0.52 | point_in_time · Q2FY27 · Sep-26 |
Guidance
Management reiterated FY27 guidance of mid-teens revenue growth and substantial improvement in profitability driven by second-half execution.
What management committed to
- Commercial launch [of new multiyear CDMO agrochem contract] expected towards the end of FY27, with peak realization by calendar year 2029/early 2030, annual revenue of ₹50-75 Cr at peak, and EBITDA margin well in excess of company average. — ₹50 to ₹75 Cr per year, FY30
- Annualized positive revenue impact of ~₹150 Cr from US FDA clearance [of Bangalore facility] on pharma business, with ~45-46% contribution margin. — ~₹150 Cr revenue, ~45-46% contribution, 12 months post FDA clearance
- Crop Protection EBITDA margins will be well in excess of 17-18% going forward [driven by CDMO mix shift and capacity utilization recovery]. — >18% EBITDA margin, FY30
- Oncology product launch [in pharma business] very shortly [post-call]. — FY28
- Personal Care business majority [will be] CDMO rather than own product portfolio over the next 4 years [by ~FY31], with initial products undergoing validation and set for commercial ramp-up in next couple of months. — FY31
Key themes
Remediation progress and CDMO expansion
How the narrative shifted
- US FDA remediation and regulatory recovery: The narrative has moved from aspiration to evidence-based confidence, with the Swissmedic audit positioned as a functional equivalent to FDA clearance in maintaining customer trust.
- Diversification into Animal Health and Personal Care: Personal Care now moves beyond conceptual to physical with commercial production started, adding tangible evidence to the long-term growth thesis.
Operational commentary
- Received Certificate of GMP Compliance from Swissmedic for Bengaluru pharma facility; completed 28 customer audits successfully during the quarter.
- Signed a multi-year commercial CDMO contract with a European global agrochemical company for a specialized AI with launch expected end of FY27.
- Commenced commercial production at new multipurpose Specialty Ingredients facility at Panoli; focus now on customer validation and commercial conversion.
- Operating Pharma capacity utilization at 60-70% to accommodate stringent quality standards and upgrades ahead of target US FDA reinspection by end-FY27.
- Animal Health CDMO pipeline has 3 new KSMs under validation and 6 CDMO products under development, with 9 process patents filed in past 12 months.
Analyst Q&A
Q. Why did Pharma EBIT margin drop 900 bps to 4.6% compared to Q2FY25 on similar revenue?
Raw material price inflation and product mix reduced contribution margin, while ongoing US FDA remediation costs added approximately ₹20 Cr annually to operating fixed costs.
Q. What is the peak revenue potential and margin profile of the new European agrochem CDMO contract?
Peak realization is estimated at ₹50-75 Cr annually by CY29/early 2030 at high EBITDA and contribution margins well above company average, supported by complete backward integration into key starting materials.
Q. Can management break down the revenue contribution between Gabapentin and non-Gabapentin products for the quarter?
Management declined to disclose the specific breakdown, stating only that Gabapentin's revenue share within the pharma portfolio continues to decrease year-on-year.
Research and educational content only. Not investment advice.